Iovance Biotherapeutics, Inc. (IOVA) Report Analysis
Corporate Events
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Dynamic Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Dynamic Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 3000 Growth Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 3000 Growth Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Value Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Value Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell Midcap Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell Midcap Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell Small Cap Comp Growth Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell Small Cap Comp Growth Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell Midcap Value Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell Midcap Value Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell Midcap Growth Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell Midcap Growth Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Growth Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Growth Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 3000E Growth Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 3000E Growth Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 2500 Growth Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 2500 Growth Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) added to Russell 2000 Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) added to Russell 2000 Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) added to Russell 2000 Value Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) added to Russell 2000 Value Index
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) added to Russell 2000 Dynamic Index
2022-06-24 00:00:00
Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) added to Russell 2000 Dynamic Index
Iovance Biotherapeutics, Inc. Presents at MedInvest Oncology Investor Conference, Jun-28-2022 05:10 PM
2022-06-16 10:37:00
Iovance Biotherapeutics, Inc. Presents at MedInvest Oncology Investor Conference, Jun-28-2022 05:10 PM. Venue: One Vanderbilt Avenue, New York, New York, United States. Speakers: Phil Friedlander, Chief Investigator.
Iovance Biotherapeutics, Inc. Appoints Wendy L. Dixon to Board of Directors
2022-06-13 20:01:00
Iovance Biotherapeutics, Inc. announced the appointment of Wendy L. Dixon, Ph.D., to the company’s Board of Directors, effective June 10, 2022. Dr. Dixon has more than 40 years of experience in the biopharmaceutical industry, building and leading organizations and launching and growing more than 20 major global pharmaceutical products, including many highly successful multibillion dollar global brands. Dr. Dixon previously served as Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb (BMS) from 2001 to 2009. She led the global commercialization and launch strategy of eight new products and directed growth and life cycle management for in-line brands. As a member of the Executive Committee at BMS, she was deeply involved with the strategy and activities that transformed BMS into highly successful Specialty Biopharmaceutical company. Dr. Dixon also established and served as the executive sponsor for the BMS “Women’s Affinity Network,” focused on gender diversity and inclusion priorities. From 1996 to 2001, Dr. Dixon was Senior Vice President, Marketing at Merck & Co., where she was responsible in launching six new products. Previously, Dr. Dixon held executive management positions at West Pharmaceuticals, Osteotech and Centocor, as well as various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. She currently serves on the Boards of Directors of Alkermes Plc, Arvinas, Inc. and Black Diamond Therapeutics, Inc. Previously, Dr. Dixon served on the Boards of Directors of Incyte Corporation, bluebird bio, Inc., Dentsply International, Furiex Pharmaceuticals, Orexigen Therapeutics, Sesen Bio, Inc. (formerly Eleven Biotherapeutics, Inc.), Ardea Biosciences, Inc. and Voyager Therapeutics, Inc. Dr. Dixon earned a B.Sc., an M.Sc. in Natural Science, and a Ph.D. in Biochemistry at the University of Cambridge, UK.
Iovance Biotherapeutics, Inc. Presents at Stifel Virtual Cell Therapy Conference, Jun-29-2022 03:30 PM
2022-06-09 00:58:00
Iovance Biotherapeutics, Inc. Presents at Stifel Virtual Cell Therapy Conference, Jun-29-2022 03:30 PM.
Iovance Biotherapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 04:30 PM
2022-06-09 00:53:00
Iovance Biotherapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 04:30 PM. Venue: Marriott Marquis, New York City, New York, United States.
Iovance Biotherapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 03:20 PM
2022-06-09 00:51:00
Iovance Biotherapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 03:20 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Iovance Biotherapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 02:30 PM
2022-05-28 04:54:00
Iovance Biotherapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 02:30 PM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
2022-05-26 20:01:00
Iovance Biotherapeutics, Inc. reported clinical results from its C-144-01 clinical study in patients with advanced melanoma who progressed on prior anti-PD-1/L1 therapy, and if BRAF mutation positive, also on prior BRAF or BRAF/MEK inhibitor therapy. In registrational Cohort 4 (n=87), the objective response rate by an independent review committee using RECIST 1.1 criteria was 29% (95% confidence interval (CI): 19.5%, 39.4%) with three complete responses and 22 partial responses. The median duration of response in Cohort 4 by IRC was 10.4 months with a median study follow-up of 23.5 months. These data demonstrate that one-time treatment with lifileucel therapy may provide meaningful benefit in heavily pre-treated patients. Cohort 4’s findings are supported by Cohort 2 (n=66), where the ORR by IRC was 35% (95% CI: 23.5%, 47.6%) with five complete responses and 18 partial responses. The median DOR in Cohort 2 was not reached with a median study follow-up of 36.6 months. The ORR by IRC for pooled patients (n=153) from both Cohorts 2 and 4 was 31% (95% CI: 24.1%, 39.4%) and median DOR was not reached at a median study follow up of 27.6 months. Patients in Cohort 4 exhibited higher baseline disease burden in comparison to patients in Cohort 2, including a substantially higher proportion of patients with elevated baseline lactate dehydrogenase levels, a well-known negative prognostic factor (64.4% versus 40.9%), as well as a greater number of tumor lesions at baseline (83.9% versus 65.2% with more than three lesions). In addition, patients in Cohort 2 also had approximately half the cumulative duration of anti-PD-1 therapy before lifileucel therapy in comparison to patients in Cohort 4. Reduced duration of prior anti-PD-1 therapy was shown to be associated with an increase of DOR to lifileucel. The treatment-emergent adverse event profile in both cohorts was consistent with the underlying disease and known adverse event profiles of non-myeloablative lymphodepletion and interleukin-2 (IL-2) and was also consistent between Cohorts 2 and 4. Iovance plans to present additional data from Cohorts 2 and 4 at a medical meeting in the second half of 2022. The planned BLA submission for lifileucel in advanced melanoma using these data remains on track for August 2022.
Iovance Biotherapeutics, Inc. - Special Call
2022-05-26 20:01:00
To discuss the updates for the C-144-01 clinical study
Iovance Biotherapeutics, Inc. Announces Amendments to Bylaws
2022-04-29 21:13:00
On April 25, 2022, the Board of Directors of Iovance Biotherapeutics, Inc. adopted a third amendment and restatement of the Company's seconded amended and restated bylaws (the Third Amended and Restated Bylaws"), pursuant to which a new Section 2.6 was added thereto in order to implement proxy access. Section 2.6 of the Third Amended and Restated Bylaws generally allows stockholders who have continuously owned at least 3% of the outstanding shares of the Company for at least three (3) years (an Eligible Stockholder") to include one or more nominees to the Board, up to 20% of the number of directors then in office, for inclusion in the Company's annual proxy statement, subject to the election of such nominee by the stockholders, upon the satisfaction of certain conditions and requirements by the Eligible Stockholder, all as more thoroughly described in the Third Amended and Restated Bylaws.
Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2022
2022-04-27 21:02:00
Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2022, at 11:00 US Eastern Standard Time. Agenda: To elect six directors named in the proxy statement accompanying this notice to serve until the 2023 Annual Meeting of Stockholders; to approve, by non-binding advisory vote, the compensation of named executive officers; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2022; and to approve an amendment to 2018 Equity Incentive Plan (the 2018 Plan") to increase the number of shares of the Company's common stock authorized for issuance thereunder from 14,000,000 shares to 20,700,000 shares.
Iovance Biotherapeutics, Inc. - Shareholder/Analyst Call
2022-04-27 21:02:00
AGM
Iovance Biotherapeutics, Inc. Presents at Next Generation CAR & T Cell Therapies 2022, Jun-15-2022 04:45 PM
2022-04-26 15:02:00
Iovance Biotherapeutics, Inc. Presents at Next Generation CAR & T Cell Therapies 2022, Jun-15-2022 04:45 PM. Speakers: Parameswaran Hari, Senior Vice President of Clinical Science.
Informa plc, Next Generation CAR & T Cell Therapies 2022, Jun 14, 2022 through Jun 16, 2022
2022-04-26 12:45:00
Informa plc, Next Generation CAR & T Cell Therapies 2022, Jun 14, 2022 through Jun 16, 2022.
Iovance Biotherapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022
2022-04-26 11:31:00
Iovance Biotherapeutics, Inc. announced that they will report Q1, 2022 results on May 05, 2022
Iovance Biotherapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
2022-04-26 11:31:00
Iovance Biotherapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
Iovance Biotherapeutics, Inc. Presents at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Conference, Apr-26-2022 01:30 PM
2022-04-25 20:28:00
Iovance Biotherapeutics, Inc. Presents at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Conference, Apr-26-2022 01:30 PM.
Stifel, Nicolaus & Company, Incorporated, Stifel Virtual Cell Therapy Conference, Jun 29, 2022 through Jun 30, 2022
2022-04-12 12:30:00
Stifel, Nicolaus & Company, Incorporated, Stifel Virtual Cell Therapy Conference, Jun 29, 2022 through Jun 30, 2022.
Iovance Biotherapeutics, Inc. - Special Call
2022-04-06 00:00:00
MELANOMA REGULATORY AND CLINICAL UPDATES
Iovance Biotherapeutics, Inc. Announces Regulatory and Clinical Updates for Lifileucel in Melanoma
2022-04-05 20:05:00
Iovance Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has provided feedback on April 1, 2022 regarding Iovance’s proposed matrix of potency assays for its upcoming Biologics License Application (BLA) for lifileucel in metastatic melanoma. Iovance received positive feedback from the FDA on both its potency assay matrix and its proprietary cell co-culture assay included in the potency assay matrix. Based on this response, Iovance expects to request a pre-BLA meeting in July 2022 and to complete a BLA submission for lifileucel by August 2022. In addition, Iovance announced plans to open a Phase III study for lifileucel in combination with pembrolizumab for the treatment of immune checkpoint inhibitor (ICI) naïve frontline metastatic melanoma in late 2022. Updated data from the combination cohort of lifileucel and pembrolizumab in ICI naïve patients (Cohort 1A in the IOV-COM-202 study, n=12) demonstrated an overall response rate (ORR) of 67%. Eight out of 12 patients had a confirmed objective response per RECIST 1.1, including three complete responses and five partial responses. Six of the eight responders had ongoing response at the time of the last data cut, and five responders had a duration of response of more than one year. The FDA previously granted Fast Track Designation for lifileucel in combination with pembrolizumab for the treatment of ICI naïve metastatic melanoma based on the unmet medical need and potential advantages for this combination over available care.
Iovance Biotherapeutics, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022
2022-03-29 20:00:00
Iovance Biotherapeutics, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States.
Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022
2022-03-29 11:02:00
Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.
Chardan Capital Markets, LLC, Chardan’s 6th Annual Genetic Medicines and Cell Therapy Conference, Apr 25, 2022
2022-03-24 12:30:00
Chardan Capital Markets, LLC, Chardan’s 6th Annual Genetic Medicines and Cell Therapy Conference, Apr 25, 2022.
JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022
2022-02-16 16:45:00
JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022
2022-02-08 07:31:00
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Iovance Biotherapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021
2021-11-22 15:06:00
Iovance Biotherapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.
Iovance Biotherapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM
2021-11-18 01:10:00
Iovance Biotherapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM.
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-13 21:30:00
Iovance Biotherapeutics, Inc. announced clinical data for lifileucel in combination with pembrolizumab in patients with advanced cancers were presented in an oral session at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. Clinical data in the presentation show encouraging response rates after lifileucel plus pembrolizumab in patients with immune checkpoint inhibitor (ICI)-naïve cervical cancer, advanced melanoma, and head and neck squamous cell carcinoma (HNSCC). The clinical data also demonstrated that lifileucel can be safely combined with pembrolizumab and warrant continued investigation of tumor infiltrating lymphocyte (TIL) cell therapy combinations as early-line treatment in advanced solid tumor cancers.Early-line treatment with single-agent pembrolizumab achieves an overall response rate (ORR) of 33% in patients with advanced melanoma1 and 17% in patients with HNSCC.2 Cervical cancer patients previously treated with standard-of-care systemic therapy achieve an ORR of 11%-14% with pembrolizumab monotherapy.3 Novel early-line combination therapies are needed to improve the rate and depth of responses with manageable long-term safety. Clinical data in the SITC oral presentation included cervical cancer patients who were ICI- and chemotherapy-naïve as well as patients with ICI-naïve advanced melanoma and HNSCC. Patients across all three cohorts had high tumor burden at baseline. The ORR in all cohorts was assessed by investigator using RECIST 1.1 as follows (September 22, 2021 data cutoff): 57.1% ORR in cervical cancer (Cohort 3 in C-145-04 cervical cancer study, n=14): Eight out of 14 patients had an objective response, including one complete response (CR), six partial responses (PR), one unconfirmed PR (uPR), and five best responses of stable disease (SD). 71.4% (5/7 patients) have ongoing confirmed responses at a median study follow up of 7.6 months. 60.0% ORR in melanoma (Cohort 1A in IOV-COM-202 study, n=10): Six out of 10 patients had a confirmed objective response, including three CRs (30% CR rate) and three PRs. Three patients achieved best response of SD. One prior unconfirmed CR (uCR) and two complete metabolic responses previously reported at ASCO 2021 converted to confirmed CRs per RECIST 1.1 as presented at SITC 2021. 66.7% (4/6 patients) have ongoing confirmed responses at a median study follow up of 11.5 months. These results compare to a 33% ORR (6% CR rate) for pembrolizumab monotherapy in metastatic melanoma.1 Iovance plans to expand enrollment in this cohort. 38.9% ORR in HNSCC (Cohort 2A in IOV-COM-202 study, n=18): Seven out of 18 patients had an objective response, including one CR, one uCR, four PRs, one uPR, and seven best responses of SD. 50.0% (3/6 patients) have ongoing confirmed responses at a median study follow up of 7.8 months.
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-12 12:01:00
Iovance Biotherapeutics, Inc. announced additional clinical data for its tumor infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) who enrolled in Cohort 3B of the ongoing basket study IOV-COM-202. The results are available in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 12-14, 2021, Washington, D.C. and virtual. The results demonstrate the feasibility of TIL cell therapy in heavily pre-treated patients with NSCLC, and warrant continued investigation of LN-145 as a single-agent and in combination in patients with mNSCLC in ongoing Iovance clinical studies IOV-LUN-202 and IOV-COM-202. Following one-time treatment with LN-145 monotherapy, the overall response rate (ORR) is 21.4% in the full analysis set (n=28) and 25% in the efficacy-evaluable set (n=24), including one complete response and five partial responses (August 24, 2021 data cutoff). Two responders, including the CR, had PD-L1 negative tumors and two responders had tumors with KRAS mutations. One complete response and one partial response are ongoing at 20.7 months and 3.0 months, respectively, at a median study follow up of 9.8 months. The treatment-emergent adverse event profile is consistent with the underlying disease and known adverse event profiles of non-myeloablative lymphodepletion and IL-2. The heavily pre-treated patients in Cohort 3B had received a median of 2 prior therapies. All patients had progressed on prior immune checkpoint inhibitor (ICI) therapy and all six responders received prior chemotherapy. TIL were most commonly grown and manufactured from tumor samples resected from the lung. Iovance is currently enrolling patients in the IOV-LUN-202 clinical study to investigate LN-145 in second-line mNSCLC where patients have progressed on prior ICI and chemotherapy. More than 20 clinical sites are currently active in the U.S. and Canada.
Iovance Biotherapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 11:20 AM
2021-11-10 05:13:00
Iovance Biotherapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 11:20 AM. Venue: New York, New York, United States.
Iovance Biotherapeutics, Inc. Presents at Cowen’s 5th Annual IO Next Virtual Summit, Nov-15-2021 03:45 PM
2021-11-10 05:00:00
Iovance Biotherapeutics, Inc. Presents at Cowen’s 5th Annual IO Next Virtual Summit, Nov-15-2021 03:45 PM.
Iovance Biotherapeutics, Inc. Announces Clinical Data for Tumor Infiltrating Lymphocyte Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer Annual Meeting
2021-11-09 13:54:00
Iovance Biotherapeutics, Inc. announced the publication of abstracts with clinical data for Iovance tumor-infiltrating lymphocyte (TIL) therapy in combination with pembrolizumab in patients with advanced cancers and for Iovance TIL cell therapy in relapsed, refractory lung cancer. Additional updates will be provided at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 12, 2021 to November 14, 2021 in Washington, D.C. and virtually. Lifileucel in Combination with Pembrolizumab in Advanced Cancers: Early-line treatment with single-agent pembrolizumab achieved an overall response rate (ORR) of 33% in patients with advanced melanoma¹ and 17% in patients with head and neck squamous cell carcinoma (HNSCC). Novel early-line combination therapies are needed to improve rate and depth of responses with manageable long-term safety. Clinical data in the SITC abstract show encouraging response rates after lifileucel plus pembrolizumab in patients with immune checkpoint inhibitor (ICI)-naïve advanced melanoma and HNSCC from the IOV-COM-202 study as well as patients from the C-145-04 clinical study who were ICI- and chemotherapy-naive. The ORR in all cohorts was assessed by investigator using RECIST 1.1 and listed in the abstract as follows: Cervical cancer (Cohort 3 in C-145-04 cervical cancer study): ORR was 50.0% with five out of 10 patients who had a confirmed objective response, including one complete response (CR), four partial responses (PR), and four best responses of stable disease (SD). Metastatic melanoma(Cohort 1A in IOV-COM-202 study): ORR was 87.5% with seven out of eight patients who had a confirmed objective response, including three CRs, three PRs, one unconfirmed PR (uPR), and one best response of SD. HNSCC (Cohort 2A in IOV-COM-202 study): ORR was 42.9% with six out of 14 patients who had a confirmed objective response, including one CR, one unconfirmed CR (uCR), four PRs, and seven best responses of SD. The treatment-emergent adverse event (TEAE) profile across all cohorts was consistent with the underlying disease and known adverse event (AE) profiles of pembrolizumab, nonmyeloablative lymphodepletion (NMA-LD), and IL-2. Additional and updated results for TIL plus pembrolizumab in cervical, melanoma and HNSCC will be available in an oral presentation at SITC. LN-145 in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC): Clinical data in the abstract for Iovance TIL therapy LN-145 in relapsed/refractory mNSCLC demonstrated responses in heavily pretreated patients with NSCLC, regardless of PD-L1 expression, and warrant further investigation of LN-145 as a single-agent and in combination in patients with NSCLC in ongoing Iovance clinical studies IOV-LUN-202 and IOV-COM-202. Consistent with previously announced results, the ORR was 21.4% in the full analysis set (n=28) and 25% in the efficacy-evaluable set (n=24) from the fully enrolled Cohort 3B of the ongoing basket study IOV-COM-202. Confirmed responses included one complete metabolic response and five PRs, including two responders with PD-L1 negative tumors. TIL was most commonly harvested from lung metastases (57.1%). All patients had progressed on prior ICI therapy, including patients with oncogene-driven tumors. The TEAE profile was consistent with the underlying NSCLC and known adverse event profiles of NMA-LD and IL-2. Additional and updated data from Cohort 3B will be available in a poster at the SITC Annual Meeting.
Iovance Biotherapeutics, Inc. - Special Call
2021-11-08 10:47:00
To discuss SITC clinical data updates for Iovance TIL cell therapy in relapsed, refractory lung cancer as well as Iovance TIL in combination with pembrolizumab in patients with advanced cancers
JMP Securities LLC, JMP Securities Hematology & Oncology Summit, Dec 06, 2021 through Dec 07, 2021
2021-10-29 18:02:00
JMP Securities LLC, JMP Securities Hematology & Oncology Summit, Dec 06, 2021 through Dec 07, 2021.
Iovance Biotherapeutics, Inc. Presents at JMP Securities Hematology & Oncology Summit, Dec-07-2021 01:40 PM
2021-10-29 18:02:00
Iovance Biotherapeutics, Inc. Presents at JMP Securities Hematology & Oncology Summit, Dec-07-2021 01:40 PM. Speakers: Frederick G. Vogt, Interim President, CEO, General Counsel & Corporate Secretary.
Cowen and Company, LLC, Cowen’s 5th Annual IO Next Virtual Summit, Nov 15, 2021
2021-10-25 20:58:00
Cowen and Company, LLC, Cowen’s 5th Annual IO Next Virtual Summit, Nov 15, 2021.
Iovance Biotherapeutics, Inc. to Report Q3, 2021 Results on Nov 04, 2021
2021-10-25 20:01:00
Iovance Biotherapeutics, Inc. announced that they will report Q3, 2021 results on Nov 04, 2021
Iovance Biotherapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021
2021-10-25 20:01:00
Iovance Biotherapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021
2021-10-25 10:00:00
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
2021-09-28 21:00:00
Iovance Biotherapeutics, Inc. is celebrating the official opening of the Iovance Cell Therapy Center (iCTC). The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, manufacturing facility dedicated to producing TIL cell therapies for patients with solid tumor cancers. The current capacity is expected to meet potential demand for thousands of patients per year with multiple types of cancers, including clinical trial patients and future commercial patients. Located at 300 Rouse Boulevard and with approximately 136,000 square feet of space, the iCTC is among the large cell therapy manufacturing facilities today. The iCTC is currently supplying Iovance clinical studies, and commercial manufacturing is expected to begin after initial product approval. The iCTC was developed and built by Gattuso Development Partners, LLC and the design and construction management firm CRB. Financial incentives were provided by the Commonwealth of Pennsylvania, the City of Philadelphia, and PIDC, including the site’s designation as a Keystone Opportunity Improvement Zone, which allows incentives for business development.
Iovance Biotherapeutics, Inc. Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured At Iovance Cell Therapy Center (iCTC)
2021-09-23 11:30:00
Iovance Biotherapeutics, Inc. reported that the Iovance Cell Therapy Center (iCTC) successfully manufactured and delivered the first clinical batch of TIL cell therapy LN-145. The first Iovance clinical study participant infused with LN-145 manufactured at iCTC is enrolled in a metastatic non-small cell lung cancer (mNSCLC) cohort in the IOV-COM-202 basket study in solid tumors. The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing potentially life-saving TIL cell therapies for patients with solid tumor cancers. With approximately 136,000 square feet of space, the iCTC is among the largest cell therapy manufacturing facilities today. The iCTC is currently supplying Iovance clinical studies, and commercial manufacturing is expected to begin after initial product approval. The current capacity is expected to meet the demand for thousands of patients per year with multiple types of cancers.
Iovance Biotherapeutics, Inc. has filed a Shelf Registration in the amount of $24.96 million.
2021-09-23 00:00:00
Iovance Biotherapeutics, Inc. has filed a Shelf Registration in the amount of $24.96 million. Security Name: Common Stock Securities Offered: 1,000,000 Transaction Features: ESOP Related Offering
Iovance Biotherapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021
2021-09-06 21:40:00
Iovance Biotherapeutics, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 .
Iovance Biotherapeutics, Inc. Presents at 6th Annual CAR-TCR Summit, Aug-30-2021 02:00 PM
2021-08-27 01:42:00
Iovance Biotherapeutics, Inc. Presents at 6th Annual CAR-TCR Summit, Aug-30-2021 02:00 PM. Venue: Hynes Convention Center, Boston, Massachusetts, United States. Speakers: Madan Jagasia, Senior Vice President of Medical Affairs.
Iovance Biotherapeutics, Inc. Presents at World Orphan Drug Congress USA 2021, Aug-26-2021 11:35 AM
2021-08-20 20:21:00
Iovance Biotherapeutics, Inc. Presents at World Orphan Drug Congress USA 2021, Aug-26-2021 11:35 AM. Venue: Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States. Speakers: Phung Osborn, Exec Director US Payers Cell Therapy.
Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021
2021-08-20 17:31:00
Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021. Venue: Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States.
Iovance Biotherapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021
2021-07-29 02:31:00
Iovance Biotherapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 . Venue: Carlsbad, California, United States. Speakers: Jean-Marc Bellemin, Chief Financial Officer & Principal Accounting Officer.
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021
2021-07-22 09:08:00
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.
Iovance Biotherapeutics, Inc. to Report Q2, 2021 Results on Aug 05, 2021
2021-07-19 20:30:00
Iovance Biotherapeutics, Inc. announced that they will report Q2, 2021 results on Aug 05, 2021
Iovance Biotherapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021
2021-07-19 20:30:00
Iovance Biotherapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021
2021-07-08 08:44:00
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.
Iovance Biotherapeutics, Inc. - Special Call
2021-06-29 19:38:00
To discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer
2021-06-29 10:30:00
Iovance Biotherapeutics, Inc. announced clinical data for its tumor infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) who enrolled in Cohort 3B of the ongoing basket study IOV-COM-202. Cohort 3B enrolled patients that had progressed on prior immune checkpoint inhibitor (ICI) therapy, including patients with oncogene-driven tumors who received prior tyrosine kinase inhibitor therapy. The overall response rate (ORR) by investigator per RECIST 1.1 was 21.4% (n=28, one complete response and five partial responses) and the disease control rate (DCR) was 64.3% following one-time treatment with LN-145 monotherapy, including two responders with PD-L1 negative tumors. Median duration of response was not reached at a median study follow up of 8.2 months. The treatment-emergent adverse event profile was consistent with the underlying disease and known adverse event profiles of non-myeloablative lymphodepletion and IL-2. All patients treated in Cohort 3B received prior anti-PD-1/L1 therapy and all six responding patients also received prior chemotherapy. Historically, ORRs of approximately 20% were reported with ICIs as second-line therapy in ICI-naïve patients who progressed on front-line chemotherapy. Iovance anticipates presenting additional Cohort 3B data at a medical meeting in the second half of 2021. The Cohort 3B data using Iovance’s TIL cell therapy are the first reported clinical data on TIL administered as a one-time monotherapy in mNSCLC from a prospective, multi-center study, and add significantly to the existing scientific data previously reported by Iovance’s collaborator H. Lee Moffitt Cancer Center. Iovance also announced that it dosed the first patient in IOV-LUN-202. Iovance previously opened the IOV-LUN-202 trial to investigate LN-145 in second-line mNSCLC where patients have progressed on one prior ICI and chemotherapy. This trial is designed to be supportive of registration.
Fundamental Summary
Looking at Iovance Biotherapeutics's financials of Q1 reflected decent results. Its growth and income factors appear positive and give support for optimism regarding the likelihood of continued positive performance. Therefore, Iovance Biotherapeutics received an overall score of 68, translating into a HOLD ranking.
Iovance Biotherapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 91.61 million compared to USD 75.45 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.51 a year ago. Diluted loss per share from continuing operations was USD 0.58 compared to USD 0.51 a year ago.
Business Description
Iovance Biotherapeutics, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l’Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics in June 2017. Iovance Biotherapeutics was incorporated in 2007 and is headquartered in San Carlos, California.
Sector Overview
Iovance Biotherapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Iovance Biotherapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Assets | 701.3 | -9.8% | 74 | |
| Liabilities | 149.3 | -4.1% | 52 | |
| Price to Book | 2.8 | -41.8% | 45 | |
| Cash & Equivalents | 92.4 | 18.1% | 87 | |
| Equity | 552.0 | -11.2% | 72 | |
| EBITDA | -332.8 | -4.2% | 60 |
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -59.8 | -11.6% | 75 | |
| Net Cashflow | -39.6 | -445.5% | 77 | |
| Capital Expenditure | -38.3 | -2.0% | 69 | |
| Free Cashflow | -1.8 | -2.9% | 66 |
* All values are TTM
The below chart reflects Iovance Biotherapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Iovance Biotherapeutics's peer average final assessment score stands on 61.0, Iovance Biotherapeutics's score is 68.
- IOVA
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Iovance Biotherapeutics's stock is now priced above its 5-day, but below its 50-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a positive setup in the near-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Iovance Biotherapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 47.
5D MA
10.53
50D MA
12.32
200D MA
17.49
MACD
-0.44
RSI
7.04
STOCH
95.65
Balance Sheet Analysis
Two main balance sheet metrics are driving the positive outlook for Iovance Biotherapeutics's financial strength going forward. Iovance Biotherapeutics did a great job related to cash and cash equivalents this period, which stood at 92.4, representing a 18.1% change from the previous filing. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its cash and cash equivalents movement earned a score of 87. Also, Iovance Biotherapeutics assets on their balance sheet, moved to 701.3, which is a -9.8% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Consequently, their asset movement received a grade of 74. That said, one metric, Book Value Factors, stood out as particularly concerning. Iovance Biotherapeutics publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 2.8 and represents -41.8% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 45. Its balance sheet, therefore, earned a score of 63.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 701.3 | -9.8% | 74 |
| Liabilities | 149.3 | -4.1% | 52 |
| Price to Book | 2.8 | -41.8% | 45 |
| Cash & Equivalents | 92.4 | 18.1% | 87 |
| Equity | 552.0 | -11.2% | 72 |
The below chart describes Iovance Biotherapeutics's performance as reflected on its balance sheet with respect to its peers. While Iovance Biotherapeutics received a balance sheet score of 63, the average of its peers stands on 63.0.
- IOVA
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 0 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 2 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 4 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 9 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 10 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 11 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 16 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 18 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 22 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 26 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 27 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 28 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 30 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 40 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 42 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 44 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 47 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 57 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 73 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 74 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 75 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 94 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Iovance Biotherapeutics appears likely to maintain its strong income statement metrics, especially Return Factors. In this filing, Iovance Biotherapeutics reported a return on equity (ROE) ratio of -59.8, which represents a change of -11.6%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its return factors component earned a score of 75. That said, one metric, EBITDA, stood out as strongly negative. Iovance Biotherapeutics's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -332.8, which represents a -4.2% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 60. their income statement received an overall score of 71.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -332.8 | -4.2% | 60 |
| Return on Equity | -59.8 | -11.6% | 75 |
The below chart describes Iovance Biotherapeutics's performance as reflected on its income statement with respect to its peers. While Iovance Biotherapeutics received a income statement score of 71 , the average of its peers stands on 65.0.
- IOVA
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 0 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 2 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 4 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 9 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 10 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 11 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 16 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 18 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 22 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 26 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 27 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 28 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 30 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 40 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 42 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 47 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 73 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 74 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 94 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Iovance Biotherapeutics appears likely to maintain its strong cash flow metrics and momentum going forward. Iovance Biotherapeutics's management was effective in improving their net cash flow, which now sits at -39.6 and represents a -445.5% change from the previous report. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. Consequently, their net cash flow movement received a grade of 77. Also, Iovance Biotherapeutics's management was effective in improving its CapEx, which now sits at -38.3 and represents -2.0% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Therefore, its CapEx movement component earned a score of 69. On the other hand, Free Cash flow, jumped out as looking problematic. Iovance Biotherapeutics did a poor job related to generating and maintaining strong free cash flow this period, which stood at -1.8, representing a -2.9% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. Their free cash flow situation is more concerning relative to their peers and competitors. Its free cash flow movement, therefore, received a grade of 66. Consequently, its cash flow earned a score of 77.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -39.6 | -445.5% | 77 |
| Capital Expenditure | -38.3 | -2.0% | 69 |
| Free Cashflow | -1.8 | -2.9% | 66 |
The below chart describes Iovance Biotherapeutics's performance as reflected on its cash flow with respect to its peers. While Iovance Biotherapeutics received a cash flow score of 77, the average of its peers stands on 63.0.
- IOVA
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 0 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 2 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 4 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 9 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 10 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 11 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 16 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 18 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 22 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 26 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 27 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 28 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 30 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 40 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 42 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 47 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 73 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 74 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 94 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.